Although the seismic tremors of the COVID-19 pandemic have subsided, aftershocks are still being felt. To address the health crisis, industry and regulators collaborated to create a variety of new life sciences regulations, partnerships, and procedures. These efforts were aimed at both expediting the development of COVID-19 vaccines and treatments and ensuring a smooth flow of essential products always needed for the maintenance of healthy populations.
The life sciences industry and its regulators face the challenges of deciding which of these relationships and processes were effective, efficient, and valuable, worthy of adoption into an evolving medical ecosystem as they return to business as usual.
In December 2021, Global Regulatory Intelligence Team (GRIT) at Deloitte published Never the same again: How COVID-19 created seismic change in life sciences regulations,1 a broad look at the global pandemic response. That report offered a deep exploration of how the relationships and collaboration among life sciences companies, national health authorities, and supranational organizations had changed—and how those changes might affect the future of the life sciences industry.
This new report is an update and expansion on that effort. It chronicles developments since the those described in Never the same again, including the end of health emergencies in several jurisdictions and the continuing process of moving new vaccines, drugs, and biological products from emergency use authorization (EUA) to full commercial authorization. And it expands the scope of GRIT’s analysis beyond the original five jurisdictions (China, the European Union, India, Japan, and the United States) by reporting on five additional nations—Argentina, Canada, Colombia, Mexico, and the United Kingdom.